Cost-Effectiveness Analysis of Alemtuzumab In Comparison With Natalizumab, Intramuscular Interferon Beta-1a, Subcutaneous Interferon Beta-1b, And Fingolimod for The Treatment of Relapsing-Remitting Multiple Sclerosis In Iran

Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.1946
https://www.valueinhealthjournal.com/article/S1098-3015(17)32280-5/fulltext
Title : Cost-Effectiveness Analysis of Alemtuzumab In Comparison With Natalizumab, Intramuscular Interferon Beta-1a, Subcutaneous Interferon Beta-1b, And Fingolimod for The Treatment of Relapsing-Remitting Multiple Sclerosis In Iran
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)32280-5&doi=10.1016/j.jval.2017.08.1946
First page : A723
Section Title : Disease-Specific Studies
Open access? : No
Section Order : 1775
Categories :
Tags :
Regions :
ViH Article Tags :